ACR Convergence 2025| Video: Rheum for Everyone, Episode 26—Ableism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

From Conceptual Seedling to Tree of Knowledge

Jason Liebowitz, MD, FACR  |  October 30, 2025

In a panel discussion at ACR Convergence 2025, three experts provided insight into how mentorship, personal values and more helped them develop the skills and habits necessary to become a master clinician.

The Role of FGL-1 in Sjögren Disease

Arthritis & Rheumatology  |  October 29, 2025

Fibrinogen-like protein-1 (FGL-1) may play a key role in the onset of autoimmunity by suppressing T cell activation in primary Sjögren disease, according to findings from Otsuka et al. Their study, which examined the influence of interorgan communication on disease pathogenesis in mice models and patients with primary Sjögren disease, may help facilitate novel diagnostic or therapeutic strategies targeting immune checkpoint molecules in autoimmune diseases.

Updates on Fibromyalgia & the Quest to Alleviate Pain

Jason Liebowitz, MD, FACR  |  October 29, 2025

ACR Convergence 2025 speakers reviewed new fibromyalgia insights, from the first new drug approval since 2009 to nociplastic pain concepts & cognitive behavioral therapy.

Emerging Treatments in Psoriatic Arthritis

Ruth Jessen Hickman, MD  |  October 29, 2025

At a scientific session of ACR Convergence 2025, Alexis Ogdie, MD, discussed new and forthcoming treatments for psoriatic arthritis.

Let’s Discuss Part 2: More Insights from the ACR Convergence 2025 Review Course

Jason Liebowitz, MD, FACR  |  October 28, 2025

The Review Course at ACR Convergence 2025 provided a comprehensive update for practitioners. Highlights from the sections on cutaneous manifestations of rheumatic diseases, gout, macrophage activation syndrome and vasculitis.

Gout & Cardiometabolic Co-Morbidities

Jason Liebowitz, MD, FACR  |  October 28, 2025

ACR Convergence 2025 experts explore gout’s deep ties to MetS, insulin resistance and cardiovascular mortality, weighing new data on colchicine, febuxostat and SGLT2 inhibitors.

Let’s Discuss: Insights from the ACR Convergence 2025 Review Course

Jason Liebowitz, MD, FACR  |  October 27, 2025

The Review Course at ACR Convergence 2025 provided a comprehensive update for practitioners. Highlights from the sections on SLE and lupus nephritis, inflammatory brain diseases, drug management of rheumatic diseases and mimics of inflammatory myopathies.

FDA Approves 2 More Denosumab Biosimilars

Michele B. Kaufman, PharmD, BCGP  |  October 27, 2025

The FDA as approved the biosimilar treatments denosumab-nxxp (Bildyos) and denosumab-nxxp (Bilprevda) for all indications of denosumab, their reference product, including osteoporosis in postmenopausal women.

The Rheum Advocate: A Fresh Look for the Same Trusted Voice

From the College  |  October 21, 2025

Starting Nov. 13, the long-running ACR@Work newsletter is transforming into The Rheum Advocate, delivering the latest updates on advocacy, policy developments, clinical practice support and the issues that matter most to rheumatology professionals.

ACR Delegation to Address AI, Non-Compete Agreements at Interim AMA House of Delegates Meeting

From the College  |  October 21, 2025

The ACR’s resolutions at the Interim HOD meeting, held Nov. 14–18, will address non-compete agreements as well as the use of artificial intelligence (AI) in prior authorization processes.

  • « Previous Page
  • 1
  • …
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • 332
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences